The Impact of Pet Benefits in Your Workplace: How pet benefits provide whole-person outcomes 81% of pet parents spent over $500 a year on unexpected pet care.  In September 2025, Airvet released the results of a survey on employed pet parents. Employers spend millions on benefits, but when pet parents (70% of your population) face […]

A “North Star” for Global Employee Wellbeing in Technology As technology companies scale rapidly—entering new markets, supporting distributed teams, and competing for highly sought-after digital talent—HR leaders face growing complexity. How do you deliver a consistent employee experience without slowing innovation? How do you balance global direction with local relevance in a fast-changing regulatory and

In May 2025, Aon released the first phase of a US study of GLP-1 medications for diabetes and weight management. Across the global technology sector, employers are facing unprecedented complexity—distributed teams, dynamic regulations, and rapidly evolving expectations around pay, benefits, and wellbeing. Aon’s role is to help tech companies cut through this complexity, using data

As an employer, take action to help control healthcare costs and improve employee wellness. Obesity and associated comorbidities are prevalent and costly chronic conditions that can impact the health of individuals in your organization. Novo Nordisk WORKS™ recognizes the challenges created by obesity and aims to help your organization understand the value of chronic weight

Financial pressure is reshaping daily life. Globally, people are having to make tough choices: 44% have cut non-essential spending, 24% have reduced essential spending, and 22% are scaling back savings or debt repayments.  When so many are working hard just to stay on top of their money, HR and Reward leaders need a simpler, more consistent way to support every employee in 2026.   Financial stress

Obesity has become the most economically consequential condition affecting employer health plans. GLP-1 drugs have ignited unprecedented demand-reshaping benefit design, pharmacy spend, wellness ecosystems, and expectations for rapid weight loss. Yet the employer challenge is no longer just “Should we cover GLP-1s?” It is now “How do we manage obesity ( the associated comorbidities )

The pharmacy benefit landscape is changing faster than ever. Drug prices are climbing, new federal policies are reshaping the market and specialty therapies are redefining what “high cost” really means. As 2026 approaches, plan sponsors will face the challenge of balancing cost control with the growing demand for transparency, while keeping both budgets and member

Today’s workforce is stretched thin—balancing caregiving, health, and daily life before the workday begins. It’s no surprise that 47% of employees and 66% of CEOs report most of their stress comes from work. Yet 55% of employees believe leadership overestimates the mental health of their workplace, and many fear stigma around seeking help (APA, 2023). 

Mental health is a growing issue for employers, and the broader healthcare industry as a whole.  The rising costs tied to untreated mental health concerns are hard to ignore; employees with unaddressed symptoms can have up to 3.5 times higher healthcare costs.  As organizations turn to high-quality mental health solutions for their employees, it’s essential

Mortality from heart disease declined in the US between 1980 and 2010 due to the decrease in cigarette smoking, more effective treatment of high blood pressure and high cholesterol, and better cardiology interventions for heart attacks. But heart disease is on the rise again. At highest risk are Black and Hispanic people, and those in

HR leaders who prioritize employee well-being—spanning mental health, physical wellness, and financial resilience—drive higher workforce engagement, retention, and overall productivity.

Increasing prevalence of diet-related health conditions indicates the concept of Food as Medicine (FAM) is relevant now more than ever. FAM is defined as strategies or interventions that are coordinated with the delivery of healthcare to provide access to nutritious foods focused on prevention, management, or treatment of disease.  FAM strategies include interventions such as

At Novo Nordisk, patient safety is a top priority.  As the sole manufacturer of FDA-approved medicines containing semaglutides, Novo Nordisk is deeply concerned by companies promoting and selling non-FDA-approved knock-off drugs that claim to contain the same “semaglutide.”  As a result of the concerning dynamics in the marketplace, Novo Nordisk is committed to raising awareness